The Mutual Recognition Agreement (MRA) is an agreement between two or more countries for the mutual recognition of certain processes or procedures. The goal is to share expertise and increase the efficiency of both regulatory systems.
Image source: Pixabay
Mutual recognition of inspections in the field of drug surveillance has already been in place between the U.S. and the EU since 2017. This has so far been limited to medicines for human use. Now, however, via an announcement on the U.S. Food and Drug Administration’s (FDA) website: MRA is to be expanded to include veterinary drugs. This decision was preceded by an extensive preparatory process in which, among other things, it was examined whether the EU member states could meet the FDA requirements.
The new regulation is expected to make veterinary medicines safer and of higher quality. It also eases the burden on regulatory systems in the U.S. as well as the European Union.
